The intracellular concentration of Cl Ϫ ([Cl Ϫ ] i ) in neurons is a highly regulated variable that is established and modulated by the finely tuned activity of the KCC2 cotransporter. Despite the importance of KCC2 for neurophysiology and its role in multiple neuropsychiatric diseases, our knowledge of the transporter's regulatory mechanisms is incomplete. Recent studies suggest that the phosphorylation state of KCC2 at specific residues in its cytoplasmic COOH terminus, such as Ser940 and Thr906/Thr1007, encodes discrete levels of transporter activity that elicit graded changes in neuronal Cl Ϫ extrusion to modulate the strength of synaptic inhibition via Cl Ϫ -permeable GABA A receptors. In this review, we propose that the functional and physical coupling of KCC2 to Cl Ϫ -sensitive kinase(s), such as the WNK1-SPAK kinase complex, constitutes a molecular "rheostat" that regulates [Cl Ϫ ] i and thereby influences the functional plasticity of GABA. The rapid reversibility of (de)phosphorylation facilitates regulatory precision, and multisite phosphorylation allows for the control of KCC2 activity by different inputs via distinct or partially overlapping upstream signaling cascades that may become more or less important depending on the physiological context. While this adaptation mechanism is highly suited to maintaining homeostasis, its adjustable set points may render it vulnerable to perturbation and dysregulation. Finally, we suggest that pharmacological modulation of this kinase-KCC2 rheostat might be a particularly efficacious strategy to enhance Cl Ϫ extrusion and therapeutically restore GABA inhibition.
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epilepsy; hyperexcitability; inhibitory synaptic transmission; K-Cl cotransport; WNK kinases THE STRENGTH AND EFFICACY of hyperpolarizing synaptic inhibition via type A ␥-aminobutyric acid receptor (GABA A R) and glycine receptor (GlyR), Cl Ϫ -permeable ion channels, is modulated by the intracellular concentration of Cl Ϫ ([Cl Ϫ ] i ) in postsynaptic neurons. Genetics has firmly established the necessity of the Cl Ϫ -extruding cation-chloride cotransporter (CCC) KCC2 (SLC12A5) for establishing and maintaining the low [Cl Ϫ ] i of postsynaptic neurons that is required for inhibition (Gagnon and Delpire 2013). Within the past few years, several reviews have highlighted the role of KCC2 and its regulation in neurophysiology and its potential as a pharmacotherapeutic target for a number of neuropsychiatric disorders, like epilepsy, spasticity, neuropathic pain, and autism (Arroyo et al. 2013; Benarroch 2013; Deidda et al. 2014; Gagnon and Delpire 2013; Hartmann and Nothwang 2015; Kahle et al. 2015; Medina et al. 2014; Puskarjov et al. 2014a ). However, our knowledge of the mechanisms that regulate KCC2 activity is still rudimentary. How is KCC2 activity regulated to maintain [Cl Ϫ ] i within a precise range to ensure an appropriate strength of inhibition in particular contexts (e.g., in developing neurons or during intense neuronal activity)? Do these mechanisms become dysregulated in neurological disease? Could a more detailed biochemical knowledge of these mechanisms be exploited to treat neurological diseases featuring impaired GABA inhibition? These are important questions with potential clinical ramifications.
Here we provide an update and review of recently discovered kinase-mediated phosphoregulatory mechanisms of KCC2 that have been shown to provide an additional mode of ionic plasticity to fine-tune the inhibitory drive of neuronal circuits. Evidence has shown that the experimental modulation of KCC2 (de)phosphorylation can considerably alter the magnitude of KCC2 activity depending on the sites that are manipulated, and the recent finding that Cl Ϫ -sensitive kinases associate with and regulate KCC2 activity (Alessi et al. 2014; Friedel et al. 2015) suggests that KCC2 phosphorylation is a dynamic mechanism that changes in response to inputs from intracellular signaling cascades. For example, the dephosphorylation of KCC2 at Thr906/Th1007 stimulates KCC2 Ͼ25-fold over baseline activity levels by preventing WNK1-SPAK kinase-dependent inhibitory phosphorylation at these sites ( Titz et al. 2015) . This is the most potent known mechanism to date of KCC2 stimulation and is sufficient to trigger hyperpolarizing GABA A responses in even high extracellular K ϩ concentrations and in neurons with extremely negative resting membrane potentials (Titz et al. 2015) . Functionally, KCC2 Thr906/Thr1007 phosphorylation inhibits KCC2 in immature neurons and is necessary to maintain the depolarizing action of GABA (Friedel et al. 2015) , which has long been known to be critical for multiple aspects of brain development. Conversely, phosphorylation at Ser940 stimulates KCC2 activity by increasing its expression at the plasma membrane, decreases in Ser940 phosphorylation have been noted in rodent models of seizures (Silayeva et al. 2015) , and human mutations in KCC2 resulting in the downregulation of Ser940 phosphorylation have been associated with idiopathic generalized epilepsy (Kahle et al. 2014b ) and familial febrile seizures (Puskarjov et al. 2014b) .
Setting these recent exciting findings within a framework of systems dynamics nomenclature that has not previously been applied to cellular Cl Ϫ homeostasis, we propose a novel model in which the coupling of Cl Ϫ -sensitive regulatory kinases with KCC2 comprises a molecular "rheostat" that senses changes in [Cl Ϫ ] i , transduces this signal to KCC2, and by multisite phosphorylation appropriately tunes KCC2 activity to elicit graded changes in neuronal [Cl Ϫ ] i to modulate GABA neurotransmission. We suggest that the versatility of this adaptation mechanism, while important for homeostasis, might create susceptibility to dysregulation in disease. Finally, pharmacological modulation of this kinase-KCC2 rheostat might be a strategy to enhance Cl Ϫ extrusion and therapeutically restore GABA inhibition.
Dependence of GABA and Glycine Neurotransmission upon [Cl Ϫ ] i Homeostasis
Glutamate excitatory neurotransmission is mediated by the transmembrane movement of cations (e.g., Na ϩ ), whereas GABA A R-and GlyR-mediated synaptic neurotransmission is influenced by the electrochemical driving force for Cl Ϫ (and to a lesser extent, HCO 3 Ϫ ) across the neuronal membrane. Mature CNS neurons are hyperpolarized by the opening of a Cl Ϫ conductance associated with the activation of GABA A Rs and GlyRs, moving the membrane potential away from the threshold of action potential firing. As GABA is released from interneurons and hyperpolarizes the postsynaptic membrane of larger projection neurons, this phenomenon is called postsynaptic inhibition (Fig. 1A) . As discussed below, this is made possible by the postsynaptic neuron's [Cl Ϫ ] i , which sets the electrochemical potential equilibrium of Cl Ϫ (E Cl ) below resting membrane potential. In contrast, in the peripheral nervous system (PNS), interneurons release GABA onto terminals that are loaded with, instead of depleted of, Cl Ϫ . As GABA A Rmediated depolarization of the terminal inhibits propagation of an incoming signal from the periphery and the GABA effect on the presynaptic side, this phenomenon is called presynaptic inhibition (Fig. 1B) . In these two situations, intracellular Cl Ϫ is not at equilibrium and the opening of GABA A Rs or GlyRs hyperpolarizes or depolarizes the neuronal membrane. If Cl Ϫ was instead at equilibrium, opening of an anion conductance would fail to produce a net movement of Cl Ϫ and a change in membrane potential but would still result in an increase in membrane conductance (and decrease in resistance) leading to changes in the excitability properties of the membrane. This shunting phenomenon diminishes the efficacy of glutamatergic (excitatory) currents and is therefore "inhibitory." While these features of GABAergic and glycinergic signaling endow neurons with a remarkable functional plasticity, they also render neurons susceptible to dysfunction when [ (Donnan 1911; Glykys et al. 2014) . Additionally, the transport of Cl Ϫ across the plasma membrane does not occur in isolation but is often coupled to the movement of other ionic species and sometimes even water. All these "complicating" factors have been discussed in a recent review (Delpire and Staley 2014).
Hyperpolarizing inhibitory postsynaptic potentials were first observed in the early 1970s in cat spinal motor neurons (Llinas et al. 1974; Lux 1971 ) and consistently observed thereafter (for review see Alvarez-Leefmans and Delpire 2009a). In fact, the concept that GABA elicits membrane hyperpolarization is now textbook material and unequivocally indicates that [Cl Ϫ ] i is lower than its thermodynamic potential equilibrium concentration. As energy is required, the key question is, What type of energy is involved? The most direct source of energy and transport mechanism would be ATP hydrolysis by a Cl Ϫ pump. While some biochemical evidence for a "Cl Ϫ -ATPase" has been presented (Hattori et al. 1998) , the fact that this ATPase was sensitive to ethacrynic acid suspiciously indicated a functional coupling between Na ϩ -K ϩ -2Cl Ϫ cotransporter [which is inhibited by ethacrynic acid] and the Na ϩ -K ϩ -ATPase. This coupling introduces the concept of secondary active transport mechanisms that use the stored energy of the ion gradients generated by the primary active Na ϩ -K ϩ -ATPase. Among them are the SLC12A family transporters, also known as the cation-chloride cotransporters (CCCs). As indicated in Fig. 2B , this transport family is comprised of two subfamilies: the inward (Na ϩ dependent) transporters (such as the Na
Ϫ cotransporters) and the outward (Na ϩ independent) transporters (such as the K ϩ -Cl Ϫ cotransporters).
The Nervous System-Specific KCC2 Cotransporter
Ϫ cotransport is mediated by NKCC1 and NKCC2, encoded by SLC12A2 and SLC12A1 genes, respectively. While all K ϩ -Cl Ϫ cotransporters are expressed in the nervous system, KCC2 is the most abundant and relevant isoform in neurons (Lu et al. 1999; Payne 1997; Payne et al. 1996) . KCC2 is transcribed from two distinct promoters, giving rise to KCC2a and KCC2b (Uvarov et al. 2007) . The "b" isoform is the most abundant form of the transporter and is upregulated during postnatal brain development (Clayton et al. 1998; Lu et al. 1999) . While most of the physiology of K ϩ -Cl Ϫ cotransport was originally worked out in red blood cells (RBCs) (Lauf et al. 1992) , the functional identification of the transporter (Misgeld et al. 1986; Thompson et al. 1988 ) was made in neurons well before its cloning (Payne et al. 1996) . Tight coupling between K ϩ and Cl Ϫ transport in a strict 1:1 stoichiometry was demonstrated in rabbit RBCs (Jennings and Adame 2001) . By using the large K ϩ gradient that exists across the neuronal membrane, the cotransporter is able to drive Cl Ϫ against its electrochemical potential equilibrium, and this in a completely electroneutral fashion. Thus KCC2 is often regarded as the mechanism that behaves like a Cl Ϫ pump, creating the driving force for Cl Ϫ entry into the cell and membrane hyperpolarization upon GABA release (for reviews see Blaesse et al. 2009; Delpire 2000; Kahle et al. 2008b) .
Is KCC2 responsible for setting [Cl Ϫ ] i or does it instead provide an efficient pathway for the movement of Cl Ϫ across the neuronal membrane? These two functions are interconnected and not easily distinguishable. The fact that KCC2 provides a rapid and efficient pathway for Cl Ϫ recovery after loading has been demonstrated experimentally (Rivera et al. 
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1999; Zhu et al. 2005 ). Opening of GABA-mediated Cl Ϫ conductance results in Cl Ϫ entry in the neuron, which is enhanced by frequent depolarization of the membrane upon sustained excitatory activity. Thus, as timing is a key factor, the ability of the neuron to promptly restore its Cl Ϫ concentration after loading is critical. In a mature neuron this function is fulfilled by KCC2, and a brisk postnatal upregulation of KCC2 activity is indeed required for the excitatory-inhibitory GABA sequence during neurodevelopment. Molecular genetics has shed particular light on the necessity of KCC2 for neuronal Cl Ϫ homeostasis and GABA/glycine function: genetic knockout of KCC2 in mice (Hubner et al. 2001; Khalilov et al. 2011; Zhu et al. 2005 Zhu et al. , 2008 , flies (Hekmat-Scafe et al. 2006) , and worms ) elevates neuronal [Cl Ϫ ] i , depolarizes the equilibrium potential of GABA (E GABA ), impairs inhibition, and causes neuronal hyperexcitability. A similar electrophysiological phenotype is seen in multiple models of neurological and psychiatric disease associated with decreased functional expression of KCC2, including autism (Cellot and Cherubini 2014), schizophrenia (Hyde et al. 2011; Kalkman 2011) , epilepsy (Kahle et al. 2014b; Silayeva et al. 2015) , spasticity (Boulenguez et al. 2010) , and neuropathic pain (Coull et al. 2003) . These data collectively reveal the necessity of KCC2 for the homeostasis of neuronal [Cl Ϫ ] i and appropriate function of GABA. However, homeostasis implies the existence of mechanisms that sense perturbations and initiate dynamic, adaptive responses to restore equilibrium. Have we been thinking about KCC2 activity in too static a manner?
Despite variations in the external environment, the internal milieu is kept relatively constant, allowing biological processes to proceed (Bernard 1878). "Homeostasis" describes how key variables in the internal milieu are maintained within an acceptable range by feedback mechanisms that compare the actual value of the so-called "regulated variable" (e.g., blood glucose or blood pressure) to a desired value or set point (Cannon 1929; Hardy 1965) . In contrast, "controlled variables" are activities, or rates, of the processes that contribute to the stability of the regulated variables (e.g., the rate of insulin secretion regulates blood glucose concentration or the rate of renal NaCl reabsorption regulates intravascular blood volume) (Cabanac 2006) . In the nomenclature of systems dynamics, regulated variables are the "Stocks" and controlled variables the "Flows" of a system. Flows increase (in-flows) or decrease (out-flows) the value of the regulated variable depending on physiological need, or in response to pathophysiological perturbation.
Given (Titz et al. 2015) . This first starts at the transcriptional level, where expression of KCC2 (and possibly NKCC1) is regulated in both temporal and spatial fashions (Clayton et al. 1998; Dzhala et al. 2005; Lu et al. 1999; Plotkin et al. 1997; Rivera et al. 1999) . Expression of NKCC1 and KCC2 is also influenced by epigenetic factors (Lee et al. 2010a; Yeo et al. 2012) . A second step of regulation involves the insertion and retrieval of KCC2 to and from the plasma membrane, respectively-a process that is in part modulated by phosphorylation at residue Ser940. Indeed, protein kinase C (PKC) directly phosphorylates KCC2 at Ser940 (Lee et al. 2007 ), thereby stimulating cell surface expression and intrinsic transport rate of KCC2, leading to an overall increase in transporter activity. Reversibly, dephosphorylation of Ser940 is thought to mediate an activity-dependent reduction of KCC2 function through a decrease in transporter stability at the plasma membrane (Lee et al. 2010b ) and/or enhanced endocytosis (Chamma et al. 2013) . Note that cell surface KCC2 expression occurs predominantly at synaptic densities (Báldi et al. 2010; Chamma et al. 2013) . Interestingly, this effect is in opposite direction to the effect of PKC on NKCC1 cell surface expression (Mykoniatis et al. 2010 ). Finally, fine-tuning of KCC2 activity occurs by kinases and phosphatases affecting the intrinsic transport properties of the transporter. Fine-tuning could also be activity dependent and thus part of plasticity of the inhibitory system, as indicated by two independent mechanisms. The first mechanism involves intracellular Ca 2ϩ and control of gene expression, with depolarizing responses in immature neurons raising intracellular Ca 2ϩ levels that result in increased KCC2 expression (Ganguly et al. 2001) . A second mechanism likely involves changes in [Cl Ϫ ] i and control of KCC2 transport activity by the SPAK/ OSR1 (Gagnon et al. 2006a ) and WNK kinases (Piala et al. 2014) , the activities of which are sensitive to the surrounding Cl Ϫ concentration (see below). Work in the late 1980s and early 1990s established that K ϩ -Cl Ϫ cotransport activity is modulated by phosphorylationdephosphorylation mechanisms (Jennings and al-Rohil 1990; Jennings and Schultz 1991; Sachs 1988 ). The transporter is stimulated by okadaic acid and calyculin A, indicating that protein phosphatase 1 and 2A (PP1 and PP2A)-dependent dephosphorylation is important for KCC activation in certain cellular contexts, such as in response to cell swelling. This property was later demonstrated with human KCC2 (Song et al. 2001) . Note that this is opposite to the regulation of the Na ϩ -dependent CCCs like NKCC1, which are stimulated by phosphorylation instead of dephosphorylation (Lytle and Forbush 1992) . This regulation is reminiscent of the opposite effects of osmolarity on both types of cotransporters, with KCCs activated by hypotonicity and the NKCCs activated by hypertonicity (Jennings and Schultz 1991; Lytle and Forbush 1992) . This "yin-and-yang" of NKCC1 vs. KCC2 regulation suggested that a common regulatory mechanism is at play for the two subfamilies of transporters, at least in certain cellular contexts. Over the last decade, yeast two-hybrid screens and the genetic investigation of rare Mendelian disorders have identified key regulatory kinases of the CCCs ( The current model of WNK-SPAK/OSR1 kinase-mediated regulation of the CCCs (Fig. 4) based on heterologous expression of WT and mutant transporters and kinases proposes that WNK kinases lie upstream of the SPAK/OSR1 (Gagnon et al. 2006a (Gagnon et al. , 2007a Vitari et al. 2005 Vitari et al. , 2006 . Through protein- Fig. 4 . Regulation of KCC2 by phosphorylation. A: opposite to NKCC1, it is dephosphorylation that activates KCC2. The kinases that stimulate NKCC1 and inhibit KCC2 are SPAK or OSR1 (mammalian Ste20p-like kinases). Their activity is also dependent on phosphorylation by upstream WNK kinases. B: equilibrium between silent and active transporter in the membrane involves the phosphorylation of 2 carboxy-terminal tail threonine residues (Thr906 and Thr1007). Stability of the transporter at the membrane depends on the phosphorylation status of neighboring residue Ser940. The activity and phosphorylation status of KCC2 at Thr906 and Thr1007 of retrieved transporters is unknown.
protein interaction via an RFxV (Arg-Phe-Xaa-Val) motif in the WNK kinases and the CCCs, and a so-called 92-residue CCT (conserved COOH terminal) domain in the SPAK/OSR1 kinases, WNKs phosphorylate and activate SPAK/OSR1, which in turn bind to the CCCs at their amino terminus and phosphorylate Thr or Ser residues at the amino terminus of the NKCCs or the carboxy terminus of the KCCs. Phosphorylation occurs at Thr207, Thr212, and Thr217 for human NKCC1 (Darman and Forbush 2002; Vitari et al. 2006 ) and Thr906 and Thr1007 for human KCC2 (Rinehart et al. 2009 ). A recent study has shown that SPAK/OSR1 directly phosphorylates KCC2 on Thr1007 (and KCC3 at the homologous residue, Thr991) (de Los Heros et al. 2014) .
Through systematic alanine mutagenesis of known Ser/Thr/ Tyr phosphosites (genetically preventing phosphorylation and mimicking dephosphorylation), Titz and coworkers recently demonstrated that modulation of the phosphorylation state of KCC2 at specific residues in the carboxy terminus can significantly enhance or diminish KCC2 activity (Titz et al. 2015) . Mutagenesis increased KCC2 activity in the following order: T1087A (smallest increase), T6A, KCC2-WT, S25A ϩ S26A, S937A, T1007A, T906A ϩ T1007A (largest increase). These data corroborated and extended earlier work in HEK293 cells (de Los Heros et al. 2014; Rinehart et al. 2009) (Thompson and Gahwiler 1989) , thereby counteracting increased Cl Ϫ influx through conductive pathways and maintaining an adaptive, strong hyperpolarizing inhibition. KCC2 Thr906/Thr1007 dephosphorylation might similarly be exploited during acute shifts in the membrane potential to more negative values (e.g., through activation of a K ϩ conductance), allowing the maintenance of hyperpolarizing GABA inhibition.
The activities of the NKCCs and the KCCs are reciprocally responsive to changes in [Cl Ϫ ] i that parallel their phosphorylation state (Alessi et al. 2014; Gagnon et al. 2006b; Kahle et al. 2010) . Cl Ϫ directly binds to the catalytic site of WNK1 and stabilizes the inactive conformation of the kinase to prevent autophosphorylation and activation (Piala et al. 2014) . Cl Ϫ has also been shown to directly inhibit SPAK/OSR1 kinase activity (Gagnon et al. 2006a (Fig. 3) , the WNK-SPAK/OSR1 kinases could be considered Controllers whose level of autophosphorylation would encode specific values of [Cl Ϫ ] i , and this change in catalytic activity would then get transduced as a signal to elicit changes in KCC2 (and possibly NKCC1) phosphorylation and activity. As such, a WNK1 and possibly SPAK/OSR1 Cl Ϫ sensor would perform similarly to other Controllers in homeostatic circuits, such as TRP channels, ASICs, and GPCRs, which monitor temperature, pH, and fatty acids, respectively (Briscoe et al. 2003; Oh et al. 2010) .
Developmental Cl Ϫ Rheostasis and the GABA ExcitatoryInhibitory Sequence
Could a WNK1-SPAK kinase-KCC2 coupled rheostat be effective in the developmental excitatory-inhibitory GABA sequence? Depolarizing and even excitatory action of GABA due to elevated [Cl Ϫ ] i is an evolutionarily conserved hallmark of immature neurons (Ben-Ari et al. 1989; Owens et al. 1996) that is required for neuronal proliferation, migration, and synaptogenesis (Aguado et al. 2003; Bortone and Polleux 2009; Fiumelli et al. 2013) and is related to the delayed postnatal increase in Cl Ϫ -extruding KCC2 cotransporter activity (Rivera et al. 1999 ). However, the mechanisms underlying the developmental switch in KCC2 activity are not well understood, and it is unclear whether changes in the amount of KCC2 protein alone, or changes in transporter regulation, might also be involved in the net increase of KCC2 activity. Previous work has shown a discrepancy between the protein expression of KCC2 and the KCC2-dependent Cl Ϫ extrusion capacity of immature neurons, suggesting other factors (Blaesse et al. 2006 ). In addition, other work has shown that the overall expression level of KCC2 is high enough in neonatal hippocampus that rapid, activity-dependent stimulation of KCC2 can elicit a negative shift in E GABA close to the adult level (Khirug et al. 2010) . We recently showed that KCC2 is more highly phosphorylated at Thr906/Thr1007 in immature neurons compared with mature neurons and that the cotransporter forms a physical complex with WNK1 and SPAK in the developing brain (Friedel et al. 2015) . Dominant-negative mutation, genetic knockdown, or chemical inhibition of WNK1 in immature neurons (but not mature neurons) is sufficient to trigger a hyperpolarizing shift in GABA activity by enhancing KCC2-mediated Cl Ϫ extrusion secondary to a reduction of Thr906/Thr1007 inhibitory phosphorylation (Friedel et al. 2015) . These results extended previous work by Rinehart et al. (2009) , who showed that KCC2 Thr906 phosphorylation inversely correlates with KCC2 activity in the developing mouse brain, and Inoue et al. (2012) , who showed a phosphorylationdependent inhibitory effect of taurine on KCC2 activity in immature neurons that was recapitulated by WNK1 overexpression in the absence of taurine. Together, these compelling data suggest that a postnatal decrease in WNK1-regulated inhibitory phosphorylation of KCC2 also contributes to increased KCC2 function (Fig. 5) , and thus to the excitatory-toinhibitory GABA shift that occurs during development. This also raises the possibility that dysfunctional phosphoregulation Review of these sites could be important in certain neurodevelopmental pathologies, like autism or neonatal seizures. An important issue of future investigation will be to determine how the increased levels of Cl Ϫ in immature neurons affect WNK1 kinase activity. Could taurine, a factor known to activate WNK1 in immature neurons, achieve this by decreasing the sensitivity of WNK1 to Cl Ϫ ?
Multisite Phosphorylation: Combinatorial Control of KCC2 by Different Signaling Inputs
KCC2 contains multiple phosphorylation sites that are targets of different kinases, increasing the combinatorial number of transporter states. Indeed, residue Ser940, identified by the Moss lab, is probably the functionally best-characterized KCC2 phosphorylation site to date (reviewed in Kahle et al. 2013 ) and already found to have clinical relevance in humans (Kahle et al. 2014b) . Similarly, the dephosphorylation of these residues is mediated by different phosphatases, which are themselves are highly regulated molecules. In neurons, glutamate-induced NMDA receptor activation and the associated influx of Ca 2ϩ promote PP1-dependent KCC2 Ser940 dephosphorylation that coincides with a deficit in hyperpolarizing GABAergic inhibition resulting from the loss of KCC2 activity (Lee et al. 2011) . This is interesting but raises the question of how PP1 might be utilized to activate KCC2 via Thr906/ Thr1007 dephosphorylation but also inhibit KCC2 via Ser940 dephosphorylation. Such an effect could be achieved by tethering PP1 activity to different regulatory subunits. Or, perhaps like NKCC1, KCC2 could itself serve as the PP1 regulatory subunit or scaffold affecting not only the phosphorylation state of the cotransporter but also the phosphorylation status of kinases that are bound to it (Darman et al. 2001; Gagnon et al. 2007b) . Interestingly, Silayeva et al. recently found that status epilepticus (SE), as modeled by kainate injection in mice, results in the glutamate-dependent dephosphorylation (and subsequent internalization of KCC2) of Ser940 and that kainate injection in KCC2 Ser940Ala knockin mice induced lethality and subsequent entrance into SE within 30 min (Silayeva et al. 2015) . Impaired KCC2 activity related to a maladaptive decrease in Ser940 phosphorylation has also proven relevant for the adaptive and pathological endocrine response to stress (MacKenzie and Maguire 2015; Sarkar et al. 2011 ) and spasticity associated with brain and spinal cord injury (Toda et al. 2014) . Recent work by the Nothwang laboratory has identified other potential sites of KCC2 phosphorylation, including Ser937 (Weber et al. 2014) . A genetic mutant KCC2 (S937D), mimicking phosphorylation, results in a significant upregulation of transport activity. The physiological relevance of this site has yet to be determined.
Kinase-KCC2 Coupling: Versatility and Vulnerability
The versatility and flexibility of kinase-controlled KCC2 regulation may enable efficient adaptation to physiological stress but may also expose the systems in which it operates to dysregulation and the development of disease. In contrast to homeostatic systems with fixed set points, those with adjustable set points are more capable of responding to perturbations but are also more vulnerable to dysregulation (Kotas and Medzhitov 2015) . Diseases, acute or chronic, can result when homeostatic systems become locked in maladaptive alternative, "stable" states (Bateson et al. 2004) .
A great genetic example of this is pseudohypoaldosteronism type II (OMIM 145260; PHAII), a human autosomal dominant disease featuring NaCl-sensitive hypertension due to constitutive activity of the thiazide-sensitive NCC, a close renalspecific cousin of KCC2. PHAII results from dysregulated WNK1-mediated NCC phosphorylation via SPAK kinase, and WNK1 mutations result in constitutively phosphorylated and active NCC. In the kidney DCT, low [Cl Ϫ ] i stimulates WNK kinases to phosphorylate and activate NCC . Could injury-induced (e.g., inflammation or ischemia) or genetically encoded derangements in WNK kinase-mediated Cl Ϫ sensing inappropriately change the Cl Ϫ set point and thereby, in analogous fashion to its renal phenotype, cause dysregulated signaling output to KCC2, locking KCC2 activity in "inappropriate" state? Relevant for this hypothesis is the finding that mutations in the nervous system-specific isoform of WNK1, WNK1/HSN2, cause a separate disease named hereditary sensory and autonomic neuropathy type II (HSA-NII), featuring congenital pain insensitivity (OMIM 201300) (Shekarabi et al. 2008) . WNK1/HSN2 is highly expressed in the dorsal horn of the spinal cord, an important site of pain processing and KCC2 function. Could mutation in WNK1/ HSN2 alter the KCC2-dependent Cl Ϫ handling of dorsal horn postsynaptic neurons and thereby dysregulate GABA A R-mediated signaling in HSANII patients? Decreased KCC2 activity, higher neuronal [Cl Ϫ ] i , and disinhibited GABA signaling accompany multiple diseases associated with ischemia and inflammation, including neuropathic pain resulting from peripheral nerve injury (Coull et al. 2005 ), motor spasticity due to spinal cord injury (Boulenguez et al. 2010) , or ischemic stroke (Jaenisch et al. 2010; Toda et al. 2014) . Inflammation is a usually protective response that is triggered to restore function when homeostatic mechanisms fail. However, to do this, inflammatory signals target the same nodes that normally execute homeostatic functions, altering the flow of Plants or the sensitivity of Controllers to elicit set-point Fig. 5 . Developmental regulation of KCC2 function. During development, expression of KCC2 increases. We hypothesize that during this increased expression the cotransporter is mostly phosphorylated at residues Thr906 and Thr1007 and therefore functionally silent. Upon neuronal maturation, the level of phosphorylation decreases and the number of active transporters in the membrane (area under blue curve) increases. Thus the KCC2 activity, which increases during development, is a combination of an increased number of transporters and increased activity of these transporters by dephosphorylation.
changes that, with chronicity, can turn maladaptive and result in chronic disease states (Chovatiya and Medzhitov 2014; Kotas and Medzhitov 2015) . The normal kinase signaling pathways that dynamically regulate KCC2, which, like other cellular signaling cascades, have a multiplicity of other functions, may become inappropriately activated by inflammation or associated forms of cell stress (e.g., osmotic) and trigger maladaptive set-point changes in [Cl Ϫ ] i . For example, it is interesting that KCC2, which mediates isotonic Cl Ϫ transport for the majority of its functions in the CNS, has evolutionarily retained the swelling-regulated dephosphorylation mechanism (Thr906/Thr1007) operative in the other KCCs for cell volume homeostasis in other cell types, like RBCs. This precise and powerful mechanism of KCC regulation has likely been coopted and retained in the evolutionary toolbox for nonswelling purposes for KCC2 (e.g., in the developmental switch in GABA function, see above). However, extracellular osmotic stress, as can occur in the context of inflammation and tissue injury due to blood-brain barrier breakdown and cell lysis, could trigger the inappropriate activation of this phosphorylation mechanism not usually exposed to changes in osmotic stimuli in the healthy CNS.
Targeting Kinase-KCC2 Coupling: a Method of Therapeutically Fine-Tuning GABA Activity?
Paradoxically, the adjustability of a kinase-KCC2 rheostat might represent a particularly effective mechanism that could be pharmacologically exploited to restore ionotropic inhibition. Given the limitations of targeting the GABA system directly (e.g., with benzodiazepines or barbiturates), an alternative approach for psychotropic and analgesic drug development has been the concept of facilitating neuronal Cl Ϫ extrusion to restore GABAergic inhibition by activating KCC2 (Doyon et al. 2013; Kahle et al. 2014a) . Recently, a few groups have developed innovative high-throughput assays to screen for compounds that modulate KCC2 activity (Delpire et al. 2009 (Delpire et al. , 2012 Gagnon et al. 2013 ), and one drug shows promise as a KCC2-dependent Cl Ϫ extrusion enhancer with therapeutic effect in a model of neuropathic pain (Gagnon et al. 2013) . These early but encouraging results require validation, but they establish the validity in vivo of the concept of GABA modulation via the pharmacological targeting of CCC-dependent Cl Ϫ transport (Gagnon et al. 2013; Kahle et al. 2014a; Kaila et al. 2014) . Could CCC phosphoregulatory mechanisms, normally employed to modulate transporter activity in response to perturbation or biological need, be harnessed to stimulate the KCCs (or inhibit NKCC1) for therapeutic benefit in disease states featuring an accumulation of intracellular Cl Ϫ ? Coincident inhibition of NKCC1-mediated Cl Ϫ loading and activation of KCC2-mediated Cl Ϫ extrusion via WNK-SPAK kinase inhibition could be one such approach . Targeting NKCC1/KCC2 activity would not affect neuronal excitability directly but would modulate the efficacy of endogenous GABAergic inhibition, potentially yielding increased specificity and wider therapeutic windows. All other efforts at developing CCC inhibitor drugs to date have focused on targeting NKCC1 and KCC2 individually. Because CCCs also work in concert with one another and other Cl Ϫ channels to achieve homeostasis, it is unknown whether targeting one CCC (e.g., NKCC1) could be compensated by other CCCs.
Since WNK-SPAK/OSR1 kinase cascade regulates both NKCC1 and KCC2, but do so in reciprocal fashion, kinase inhibition would be expected to promote combined NKCC1 inhibition and KCC2 stimulation (Alessi et al. 2014; de Los Heros et al. 2014; Gagnon and Delpire 2012; Kahle et al. 2008a; Rinehart et al. 2009) (Fig. 3) , yielding a net facilitation of Cl Ϫ extrusion. Therefore, WNK-SPAK inhibition may be more efficacious than poorly CNS-penetrant loop diuretics (bumetanide; see Tyzio et al. 2014) or KCC2 activators (Gagnon et al. 2013) .
Moreover, since the WNK kinases might also be the Cl Ϫ sensors that detect changes in intracellular Cl Ϫ (Piala et al. 2014) , inhibiting these molecules might prevent feedback mechanisms that would counter the effects of targeting NKCC1 or KCC2 alone. The approach might be a tenable method of restoring ionotropic inhibition for a wide range of disorders, including both neurodevelopmental diseases such as neonatal seizures, autism, and schizophrenia and adult disorders such as neuropathic pain, temporal lobe epilepsy, and spasticity.
Another alluring possible therapeutic strategy is preventing maladaptive increases in KCC2 Ser940 dephosphorylation. Since seizures affect GABA function of corticotropin-releasing hormone, which acts on the hypothalamic-pituitary-adrenal (HPA) axis (O'Toole et al. 2014) , could antagonizing KCC2 Ser940 dephosphorylation counter the hyperexcitability of the HPA axis in disorders like anxiety, major depression, and posttraumatic stress disorder? These are fascinating questions worthy of future investigation. These findings may be relevant for human epileptigenesis; indeed, mutations in human KCC2 associated with idiopathic generalized epilepsy at Arg952 and/or Arg1049 have been shown to disrupt the phosphorylation of KCC2 at Ser940 (Kahle et al. 2014b) .
Conclusions
Regulated phosphorylation of KCC2 likely represents an effective mechanism to fine-tune [Cl Ϫ ] i , and by doing so, modulate GABA/glycineric inhibition and neuronal plasticity. This is likely achieved by multiple signaling pathways phosphorylating different residues, such as PKC modulation of Ser940, which are operative in specific physiological contexts. Recent work has shown that the experimental modification of KCC2 phosphorylation can considerably affect KCC2 activity, with transport rates approaching thermodynamic equilibrium when, for example, Thr906/Th1007 phosphorylation is prevented (Titz et al. 2015) . This suggests that inhibition of KCC2 Thr906/Thr1007 phosphorylation directly (via drug or antibody binding) or indirectly (e.g., via kinase inhibitors that target WNK-SPAK kinase signaling) might be a novel way of facilitating neuronal Cl Ϫ extrusion for therapeutic effect. The regulated phosphorylation of KCC2 Ser940 also appears important for KCC2 function and has implications for human diseases such as idiopathic generalized epilepsy, febrile seizures, and SE. Using the nomenclature and concepts of systems dynamics, we offered a model of kinase-KCC2 function as a rheostat of neuronal Cl Ϫ homeostasis, and suggest that the "tunability" of this mechanism is a two-edged sword that, while allowing for homeostatic adaptation, may be more vulnerable to genetically encoded or injury-induced set-point changes. Ultimately, some neuropsychiatric disorders associ- 
